Cargando…

Prostacyclin Suppresses Twist Expression in the Presence of Indomethacin in Bone Marrow-Derived Mesenchymal Stromal Cells

BACKGROUND: Iloprost, a stable prostacyclin I(2) analogue, seems to have an osteoblast-protective potential, whereas indomethacin suppresses new bone formation. The aim of this study was to investigate human bone marrow stromal cell (BMSC) proliferation and differentiation towards the osteoblastic l...

Descripción completa

Detalles Bibliográficos
Autores principales: Kemper, Oliver, Herten, Monika, Fischer, Johannes, Haversath, Marcel, Beck, Sascha, Classen, Tim, Warwas, Sebastian, Tassemeier, Tjark, Landgraeber, Stefan, Lensing-Höhn, Sabine, Krauspe, Rüdiger, Jäger, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4238757/
https://www.ncbi.nlm.nih.gov/pubmed/25382306
http://dx.doi.org/10.12659/MSM.890953
_version_ 1782345507245391872
author Kemper, Oliver
Herten, Monika
Fischer, Johannes
Haversath, Marcel
Beck, Sascha
Classen, Tim
Warwas, Sebastian
Tassemeier, Tjark
Landgraeber, Stefan
Lensing-Höhn, Sabine
Krauspe, Rüdiger
Jäger, Marcus
author_facet Kemper, Oliver
Herten, Monika
Fischer, Johannes
Haversath, Marcel
Beck, Sascha
Classen, Tim
Warwas, Sebastian
Tassemeier, Tjark
Landgraeber, Stefan
Lensing-Höhn, Sabine
Krauspe, Rüdiger
Jäger, Marcus
author_sort Kemper, Oliver
collection PubMed
description BACKGROUND: Iloprost, a stable prostacyclin I(2) analogue, seems to have an osteoblast-protective potential, whereas indomethacin suppresses new bone formation. The aim of this study was to investigate human bone marrow stromal cell (BMSC) proliferation and differentiation towards the osteoblastic lineage by administration of indomethacin and/or iloprost. MATERIAL/METHODS: Human bone marrow cells were obtained from 3 different donors (A=26 yrs/m; B=25 yrs/f, C=35 yrs/m) via vacuum aspiration of the iliac crest followed by density gradient centrifugation and flow cytometry with defined antigens (CD105+/73+/45−/14−). The cells were seeded and incubated as follows: without additives (Group 0; donor A/B/C), with 10(−7) M iloprost only (Group 0+ilo; A/B), with indomethacin only in concentrations of 10(−6) M (Group 1, A), 10(−5) M (Group 2, B), 10(−4) M (Group 3, A/B), and together with 10(−7) M iloprost (Groups 4–6, A/B/C). On Day 10 and 28, UV/Vis spectrometric and immunocytochemical assays (4 samples per group and donor) were performed to investigate cell proliferation (cell count measurement) and differentiation towards the osteoblastic lineage (CD34−, CD45−, CD105+, type 1 collagen (Col1), osteocalcin (OC), alkaline phosphatase (ALP), Runx2, Twist, specific ALP-activity). RESULTS: Indomethacin alone suppressed BMSC differentiation towards the osteoblastic lineage by downregulation of Runx2, Col1, and ALP. In combination with indomethacin, iloprost increased cell proliferation and differentiation and it completely suppressed Twist expression at Day 10 and 28. Iloprost alone did not promote cell proliferation, but moderately enhanced Runx2 and Twist expression. However, the proliferative effects and the specific ALP-activity varied donor-dependently. CONCLUSIONS: Iloprost partially antagonized the suppressing effects of indomethacin on BMSC differentiation towards the osteoblast lineage. It enhanced the expression of Runx2 and, only in the presence of indomethacin, it completely suppressed Twist. Thus, in the treatment of avascular osteonecrosis or painful bone marrow edema, the undesirable effects of indomethacin might be counterbalanced by iloprost.
format Online
Article
Text
id pubmed-4238757
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-42387572014-11-21 Prostacyclin Suppresses Twist Expression in the Presence of Indomethacin in Bone Marrow-Derived Mesenchymal Stromal Cells Kemper, Oliver Herten, Monika Fischer, Johannes Haversath, Marcel Beck, Sascha Classen, Tim Warwas, Sebastian Tassemeier, Tjark Landgraeber, Stefan Lensing-Höhn, Sabine Krauspe, Rüdiger Jäger, Marcus Med Sci Monit Lab/In Vitro Research BACKGROUND: Iloprost, a stable prostacyclin I(2) analogue, seems to have an osteoblast-protective potential, whereas indomethacin suppresses new bone formation. The aim of this study was to investigate human bone marrow stromal cell (BMSC) proliferation and differentiation towards the osteoblastic lineage by administration of indomethacin and/or iloprost. MATERIAL/METHODS: Human bone marrow cells were obtained from 3 different donors (A=26 yrs/m; B=25 yrs/f, C=35 yrs/m) via vacuum aspiration of the iliac crest followed by density gradient centrifugation and flow cytometry with defined antigens (CD105+/73+/45−/14−). The cells were seeded and incubated as follows: without additives (Group 0; donor A/B/C), with 10(−7) M iloprost only (Group 0+ilo; A/B), with indomethacin only in concentrations of 10(−6) M (Group 1, A), 10(−5) M (Group 2, B), 10(−4) M (Group 3, A/B), and together with 10(−7) M iloprost (Groups 4–6, A/B/C). On Day 10 and 28, UV/Vis spectrometric and immunocytochemical assays (4 samples per group and donor) were performed to investigate cell proliferation (cell count measurement) and differentiation towards the osteoblastic lineage (CD34−, CD45−, CD105+, type 1 collagen (Col1), osteocalcin (OC), alkaline phosphatase (ALP), Runx2, Twist, specific ALP-activity). RESULTS: Indomethacin alone suppressed BMSC differentiation towards the osteoblastic lineage by downregulation of Runx2, Col1, and ALP. In combination with indomethacin, iloprost increased cell proliferation and differentiation and it completely suppressed Twist expression at Day 10 and 28. Iloprost alone did not promote cell proliferation, but moderately enhanced Runx2 and Twist expression. However, the proliferative effects and the specific ALP-activity varied donor-dependently. CONCLUSIONS: Iloprost partially antagonized the suppressing effects of indomethacin on BMSC differentiation towards the osteoblast lineage. It enhanced the expression of Runx2 and, only in the presence of indomethacin, it completely suppressed Twist. Thus, in the treatment of avascular osteonecrosis or painful bone marrow edema, the undesirable effects of indomethacin might be counterbalanced by iloprost. International Scientific Literature, Inc. 2014-11-10 /pmc/articles/PMC4238757/ /pubmed/25382306 http://dx.doi.org/10.12659/MSM.890953 Text en © Med Sci Monit, 2014 This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License
spellingShingle Lab/In Vitro Research
Kemper, Oliver
Herten, Monika
Fischer, Johannes
Haversath, Marcel
Beck, Sascha
Classen, Tim
Warwas, Sebastian
Tassemeier, Tjark
Landgraeber, Stefan
Lensing-Höhn, Sabine
Krauspe, Rüdiger
Jäger, Marcus
Prostacyclin Suppresses Twist Expression in the Presence of Indomethacin in Bone Marrow-Derived Mesenchymal Stromal Cells
title Prostacyclin Suppresses Twist Expression in the Presence of Indomethacin in Bone Marrow-Derived Mesenchymal Stromal Cells
title_full Prostacyclin Suppresses Twist Expression in the Presence of Indomethacin in Bone Marrow-Derived Mesenchymal Stromal Cells
title_fullStr Prostacyclin Suppresses Twist Expression in the Presence of Indomethacin in Bone Marrow-Derived Mesenchymal Stromal Cells
title_full_unstemmed Prostacyclin Suppresses Twist Expression in the Presence of Indomethacin in Bone Marrow-Derived Mesenchymal Stromal Cells
title_short Prostacyclin Suppresses Twist Expression in the Presence of Indomethacin in Bone Marrow-Derived Mesenchymal Stromal Cells
title_sort prostacyclin suppresses twist expression in the presence of indomethacin in bone marrow-derived mesenchymal stromal cells
topic Lab/In Vitro Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4238757/
https://www.ncbi.nlm.nih.gov/pubmed/25382306
http://dx.doi.org/10.12659/MSM.890953
work_keys_str_mv AT kemperoliver prostacyclinsuppressestwistexpressioninthepresenceofindomethacininbonemarrowderivedmesenchymalstromalcells
AT hertenmonika prostacyclinsuppressestwistexpressioninthepresenceofindomethacininbonemarrowderivedmesenchymalstromalcells
AT fischerjohannes prostacyclinsuppressestwistexpressioninthepresenceofindomethacininbonemarrowderivedmesenchymalstromalcells
AT haversathmarcel prostacyclinsuppressestwistexpressioninthepresenceofindomethacininbonemarrowderivedmesenchymalstromalcells
AT becksascha prostacyclinsuppressestwistexpressioninthepresenceofindomethacininbonemarrowderivedmesenchymalstromalcells
AT classentim prostacyclinsuppressestwistexpressioninthepresenceofindomethacininbonemarrowderivedmesenchymalstromalcells
AT warwassebastian prostacyclinsuppressestwistexpressioninthepresenceofindomethacininbonemarrowderivedmesenchymalstromalcells
AT tassemeiertjark prostacyclinsuppressestwistexpressioninthepresenceofindomethacininbonemarrowderivedmesenchymalstromalcells
AT landgraeberstefan prostacyclinsuppressestwistexpressioninthepresenceofindomethacininbonemarrowderivedmesenchymalstromalcells
AT lensinghohnsabine prostacyclinsuppressestwistexpressioninthepresenceofindomethacininbonemarrowderivedmesenchymalstromalcells
AT krausperudiger prostacyclinsuppressestwistexpressioninthepresenceofindomethacininbonemarrowderivedmesenchymalstromalcells
AT jagermarcus prostacyclinsuppressestwistexpressioninthepresenceofindomethacininbonemarrowderivedmesenchymalstromalcells